Katherine Atkinson, MD
Family Medicine · Amherst, MANPI 1700849643
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,195 of the $6,098 with a category attached, or 85.2%. It is spread thinly across 40 manufacturers, the largest accounting for just 19.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,223 and has fallen 72.9% since, to $603 in 2025. Among family medicine clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 237 payments — averaging $25.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$1K
- Surgi-care, Inc.$780
- Pfizer$459
- GSK$399
- AstraZeneca$355
- Astellas Pharma US Inc$301
- plus $3K from 34 others
What the payments were for
- Speaking & faculty fees$78013%
- Food & beverage$5,19585%
- Education$1232%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 31 | $1,186 |
| Surgi-care, Inc. | 1 | $780 |
| Pfizer | 32 | $459 |
| GSK | 24 | $399 |
| AstraZeneca | 17 | $355 |
| Astellas Pharma US Inc | 10 | $301 |
| Lilly USA, LLC | 10 | $271 |
| AbbVie(2 entities) | 12 | $258 |
| Ironshore Pharmaceuticals Inc. | 3 | $232 |
| Amgen | 8 | $185 |
| Myriad Women's Health, Inc. | 1 | $166 |
| E.r. Squibb & Sons, L.L.C. | 8 | $161 |
| Biohaven Pharmaceutical Holding Company Ltd. | 26 | $150 |
| Merck | 8 | $146 |
| Paragonix Technologies, Inc. | 1 | $124 |
| Otsuka America Pharmaceutical, Inc. | 5 | $107 |
| Sanofi Pasteur Inc. | 4 | $91 |
| Novo Nordisk | 5 | $90 |
| Radius Health, Inc. | 3 | $79 |
| Therapeuticsmd, Inc. | 3 | $67 |
| Abbott | 2 | $46 |
| Indivior Inc. | 2 | $40 |
| Biohaven Pharmaceuticals, Inc. | 2 | $36 |
| Alkermes, Inc. | 2 | $34 |
| Bayer | 1 | $34 |
| Exact Sciences | 2 | $33 |
| Gilead | 1 | $29 |
| Sanofi | 1 | $26 |
| Novartis | 1 | $24 |
| Exeltis, USA Inc. | 1 | $24 |
| Tolmar, Inc. | 1 | $22 |
| Braeburn Inc. | 1 | $21 |
| IBSA Pharma Inc. | 1 | $21 |
| Teva Pharmaceuticals USA, Inc. | 1 | $18 |
| Echosens North America, Inc. | 1 | $17 |
| Amarin Pharma, Inc. | 1 | $14 |
| Redhill Biopharma Inc. | 1 | $14 |
| Organon | 1 | $13 |
| Seqirus USA Inc | 1 | $13 |
| Titan Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SPRAVATO$224
- Jornay PM 20mg capsules (Bottle of 100)$197
- myRisk$166
- BaroGuard$124
- KISUNLA$114
How this compares
$6,098 in reported general payments places this provider in the 95th percentile of 1,049 family medicine providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 48 | $47,698 |
| TrulicityDulaglutide | 26 | $30,608 |
| Nurtec OdtRimegepant Sulfate | 12 | $22,778 |
| XareltoRivaroxaban | 18 | $21,315 |
| ProliaDenosumab | 12 | $20,889 |
| MounjaroTirzepatide | 12 | $18,029 |
| Breo ElliptaFluticasone/Vilanterol | 32 | $15,072 |
| OzempicSemaglutide | 14 | $12,802 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 41 | $8,510 |
| Rosuvastatin Calcium | 195 | $6,491 |
| CreonLipase/Protease/Amylase | 11 | $5,079 |
| Estradiol | 42 | $4,475 |
| ToviazFesoterodine Fumarate | 12 | $3,517 |
| Estradiol (Twice Weekly)Estradiol | 18 | $2,801 |
| Adacel TdapDiph,pertuss(Acell),tet Vac/Pf | 36 | $2,518 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Nurtec Odt, Toviaz | $459 | $73,99372 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $271 | $48,63738 claims |
| GSKBreo Ellipta, Shingrix | $399 | $23,58373 claims |
| Johnson & JohnsonXarelto | $1,186 | $21,31518 claims |
| AmgenProlia | $185 | $20,88912 claims |
| Novo NordiskOzempic | $90 | $12,80214 claims |
| AbbVieCreon, Synthroid | $258 | $7,04050 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,049 family medicine providers in Massachusetts.
Other family medicine in Amherst
- Larry CulpepperBoston$109K
- Jennifer WeylerWorcester$105K
- Megan McCoyFramingham$75K
- Kristina GraceyWorcester$73K
- Suzanne MitchellBoston$69K
- John GrievesonLowell$24K
- James SalemisRoslindale$24K
- David FarzanLawrence$23K
- Julie JohnstonLawrence$21K
- Sanjeev SharmaFramingham$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.